首页> 外文期刊>Rambam Maimonides Medical Journal >The Role of Prophylactic Central Neck Dissection in the Treatment of Differentiated Thyroid Cancer
【24h】

The Role of Prophylactic Central Neck Dissection in the Treatment of Differentiated Thyroid Cancer

机译:预防性中央颈清扫术在分化型甲状腺癌治疗中的作用

获取原文
           

摘要

The utility and efficacy of prophylactic central neck dissection with total thyroidectomy for the treatment of differentiated thyroid cancer has been debated in the literature over the past few decades. Proponents of prophylactic central neck dissection support its routine use with the notion that it reduces local recurrence, increases accuracy in TNM staging, and reduces surgical morbidity associated with reoperation. Conversely, those against the use of routine prophylactic central neck dissection argue there is no clear evidence which shows a reduction in recurrence or added benefit to survival, while the procedure increases the risk for complications and morbidity. This article discusses the role of prophylactic central neck dissection in the setting of thyroid cancer and reviews recently published literature to evaluate efficacy and safety of this procedure.Keywords: Differentiated thyroid cancer, morbidity, prophylactic central neck dissection, recurrence, survival, treatmentINTRODUCTIONThyroid cancer is the most common endocrine malignancy, and its incidence is increasing at the highest rate among cancers in both the US and worldwide.1,2 The National Cancer Institute’s annual Surveillance Epidemiology and End Results (SEER) database estimates that there will be 62,450 new cases of thyroid cancer in the US in 2015, with an incidence of 13.5 per 100,000.1 The absolute increase in the incidence of thyroid cancer is estimated to be 9.4 per 100,000 individuals, with papillary thyroid cancer (PTC) accounting for the majority of these cases. Overall, differentiated thyroid cancer (DTC) has a 10-year survival rate of greater than 90%. However, despite its promising survival rate, local recurrence occurs in 20%–30% of papillary thyroid cancer patients due to clinically undetectable metastasis to cervical lymph nodes.3 Cervical lymph node metastases are a common feature of PTC, occurring primarily in the central compartment (level VI) with an incidence between 20% and 90% (average 60%).4–8 Conversely, follicular thyroid cancer (FTC) often spreads hematogenously, and rarely metastasizes to the cervical lymph nodes.9 Hurthle cell thyroid cancer (HTC) is a rare and aggressive form of differentiated thyroid cancer of follicular cell origin; HTC displays a lower rate of cervical lymph node metastasis compared to PTC.9The central compartment is bounded by the hyoid bone (superior), carotid artery (lateral), and sternal notch or innominate artery (inferior). The American Thyroid Association (ATA) defines central compartment neck dissection as “comprehensive, compartment-oriented removal of the prelaryngeal and pretracheal nodes and at least one paratracheal lymph node basin.”10 The regional metastases to the cervical lymph nodes were traditionally believed to have an effect only on recurrence rate, but not mortality.5,8,11 However, in 2006, a population-based study from Sweden found lymph node metastases in both the central and lateral compartments to be a prognostic factor for patients with DTC.11 This finding complicated debate in the literature with regard to the initial treatment of differentiated thyroid cancer.5,8,11 Surgery, typically in the form of a total thyroidectomy (TT), has been accepted as the treatment of choice for most patients with differentiated thyroid cancer. There is also consensus in regard to treating patients with clinically evident level VI nodal disease with central neck dissection at the time of initial surgery.4–8 However, the addition of a prophylactic central neck dissection (PCND) to TT in clinically node-negative patients with DTC remains controversial due to lack of prospective randomized controlled studies.4,12 The ATA addresses this controversy in the 2015 American Thyroid Association Guidelines for Adult Patients with Thyroid Nodules and DTC, recommending the following for the use of PCND in the treatment of DTC:(b) Prophylactic central-compartment neck dissection (ipsilateral or bilateral) sh
机译:在过去的几十年中,关于全甲状腺切除术的预防性中央颈淋巴清扫术在分化型甲状腺癌治疗中的实用性和有效性的争论一直在文献中进行。预防性中央颈清扫术的支持者支持其常规使用,因为它可以减少局部复发,增加TNM分期的准确性并减少与再手术相关的手术发病率。相反,那些反对使用常规预防性中枢颈淋巴清扫术的人则认为,没有明确的证据显示复发减少或对生存增加了益处,而该过程却增加了并发症和发病的风险。本文探讨了预防性中央颈清扫术在甲状腺癌中的作用,并综述了最近发表的文献以评估该方法的有效性和安全性。这是最常见的内分泌恶性肿瘤,在美国和全世界的癌症中发病率均以最高的速度增长。1,2美国国家癌症研究所的年度监测流行病学和最终结果(SEER)数据库估计,将有62,450例新发2015年,美国甲状腺癌的发病率是每100,000人中有13.5人。1甲状腺癌的绝对发病率估计为每100,000人中9.4人,其中乳头状甲状腺癌(PTC)占大多数。总体而言,分化型甲状腺癌(DTC)的10年生存率大于90%。然而,尽管其生存率令人鼓舞,但由于临床上无法检测到宫颈淋巴结转移,因此甲状腺乳头状甲状腺癌患者发生局部复发的比例为20 %-30%。3中央室(VI级)的发生率在20%至90%之间(平均60%)。4-8相反,滤泡性甲状腺癌(FTC)通常是血行性扩散的,很少转移至颈淋巴结。9甲状腺细胞癌(HTC)是一种滤泡细胞起源的分化型甲状腺癌的罕见且侵袭性形式;与PTC相比,HTC的颈淋巴结转移率更低。9中央隔室由舌骨(上),颈动脉(外侧)和胸骨切口或无名动脉(下)界定。美国甲状腺协会(ATA)将中央隔室颈淋巴清扫术定义为“全面,以隔室为导向切除喉前和气管前淋巴结以及至少一个气管旁淋巴结盆。” 10传统上认为,颈部淋巴结的区域转移具有仅对复发率有影响,而对死亡率无影响。5,8,11然而,2006年,瑞典一项基于人群的研究发现,中部和侧部的淋巴结转移是DTC患者的预后因素。11对于分化型甲状腺癌的初始治疗,这一发现在文献中引起了复杂的争论。5,8,11通常以全甲状腺切除术(TT)的形式进行的手术已被接受为大多数分化型甲状腺癌患者的治疗选择。甲状腺癌。在初次手术时以中央颈淋巴结清扫术治疗具有临床上明显的VI级淋巴结病的患者也达成共识。4-8但是,临床淋巴结阴性的TT患者增加了预防性中央颈淋巴结清扫术(PCND)由于缺乏前瞻性随机对照研究,DTC患者仍然存在争议。4,12ATA在《 2015年美国甲状腺协会甲状腺结节和成年患者成年患者指南》中解决了这一争议,建议在PCND的治疗中采用以下方法DTC:(b)预防性中央室颈清扫术(同侧或双侧)sh

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号